Published in Cardiovasc Res on October 08, 2009
Acute decreases in proteasome pathway activity after inhalation of fresh diesel exhaust or secondary organic aerosol. Environ Health Perspect (2010) 0.97
The ubiquitin proteasome system and myocardial ischemia. Am J Physiol Heart Circ Physiol (2012) 0.90
Metabolomic Quantitative Trait Loci (mQTL) Mapping Implicates the Ubiquitin Proteasome System in Cardiovascular Disease Pathogenesis. PLoS Genet (2015) 0.84
Dysfunction of the ubiquitin-proteasome system in atherosclerotic cardiovascular disease. Am J Cardiovasc Dis (2015) 0.77
The Effect of Low-Dose Proteasome Inhibition on Pre-Existing Atherosclerosis in LDL Receptor-Deficient Mice. Int J Mol Sci (2017) 0.75
Changes in expression of proteasome in rats at different stages of atherosclerosis. Anat Cell Biol (2016) 0.75
Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 28.21
Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation (2006) 5.91
Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol (2007) 4.45
The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol (2008) 4.20
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res (2007) 3.85
Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res (2002) 3.69
DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev (2003) 3.67
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41
Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol (2007) 3.23
Molecular mechanisms of Nrf2-mediated antioxidant response. Mol Carcinog (2009) 2.94
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med (2009) 2.62
Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res (2007) 2.60
Chronic proteasome inhibition contributes to coronary atherosclerosis. Circ Res (2007) 2.55
Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol (2004) 2.27
The proteasomal system. Mol Aspects Med (2009) 2.19
Mapping the murine cardiac 26S proteasome complexes. Circ Res (2006) 2.17
Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and 'aggresomes' during oxidative stress, aging, and disease. Int J Biochem Cell Biol (2004) 2.15
Transcription factors: an overview. Int J Biochem Cell Biol (1997) 1.96
Ubiquitin and ubiquitin-like proteins in protein regulation. Circ Res (2007) 1.87
A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J Immunol (2009) 1.84
Up-regulation of the human gamma-glutamylcysteine synthetase regulatory subunit gene involves binding of Nrf-2 to an electrophile responsive element. Biochem Biophys Res Commun (1999) 1.81
Nitric oxide regulates transforming growth factor-beta signaling in endothelial cells. Circ Res (2005) 1.79
Morning blood pressure surge as a destabilizing factor of atherosclerotic plaque: role of ubiquitin-proteasome activity. Hypertension (2007) 1.77
Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation (2002) 1.75
Potential role of the ubiquitin-proteasome system in atherosclerosis: aspects of a protein quality disease. J Am Coll Cardiol (2008) 1.74
A functional SNP in PSMA6 confers risk of myocardial infarction in the Japanese population. Nat Genet (2006) 1.73
Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes. EMBO J (2002) 1.68
Proteasome-dependent degradation of guanosine 5'-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus. Circulation (2007) 1.63
Age-dependent declines in proteasome activity in the heart. Arch Biochem Biophys (2002) 1.52
The ubiquitin-proteasome system in cardiac physiology and pathology. Am J Physiol Heart Circ Physiol (2006) 1.47
The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended. Cardiovasc Res (2004) 1.46
Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest (2006) 1.45
Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochim Biophys Acta (2004) 1.36
4-Hydroxy-2-nonenal increases superoxide anion radical in endothelial cells via stimulated GTP cyclohydrolase proteasomal degradation. Arterioscler Thromb Vasc Biol (2007) 1.32
Negative feedback loop in T cell activation through IkappaB kinase-induced phosphorylation and degradation of Bcl10. Proc Natl Acad Sci U S A (2007) 1.28
Angiogenesis in atherogenesis. Arterioscler Thromb Vasc Biol (2006) 1.28
CD11c(+) dendritic cells maintain antigen processing, presentation capabilities, and CD4(+) T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis. Circ Res (2008) 1.26
Dysregulation of the ubiquitin-proteasome system in human carotid atherosclerosis. Arterioscler Thromb Vasc Biol (2006) 1.25
A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells. J Biol Chem (2008) 1.22
ADRP/adipophilin is degraded through the proteasome-dependent pathway during regression of lipid-storing cells. J Lipid Res (2005) 1.22
Extracellular, circulating proteasomes and ubiquitin - incidence and relevance. Biochim Biophys Acta (2008) 1.21
Inactivation of the proteasome by 4-hydroxy-2-nonenal is site specific and dependant on 20S proteasome subtypes. Arch Biochem Biophys (2006) 1.20
Mcl-1: a highly regulated cell death and survival controller. J Biomed Sci (2006) 1.17
The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes (2006) 1.16
Proteasome inhibitors: poisons and remedies. Med Res Rev (2008) 1.16
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology (2008) 1.14
Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol (2006) 1.14
Role of NFkappaB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI. Eur J Immunol (2001) 1.13
Upregulation of immunoproteasomes by nitric oxide: potential antioxidative mechanism in endothelial cells. Free Radic Biol Med (2005) 1.13
Autophagy in atherosclerosis. Curr Atheroscler Rep (2008) 1.13
Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB J (2004) 1.11
Relationships between caveolae and eNOS: everything in proximity and the proximity of everything. Am J Physiol Renal Physiol (2002) 1.11
Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells. Free Radic Biol Med (2006) 1.10
T cells in arteritis and atherosclerosis. Curr Opin Lipidol (2008) 1.10
Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment. J Am Coll Cardiol (2006) 1.09
Differential expression regulation of the alpha and beta subunits of the PA28 proteasome activator in mature dendritic cells. J Immunol (2005) 1.09
Oxidized LDLs alter the activity of the ubiquitin-proteasome pathway: potential role in oxidized LDL-induced apoptosis. FASEB J (2000) 1.08
Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Hypertension (2004) 1.08
Ubiquitin carboxyl-terminal hydrolase L1, a novel deubiquitinating enzyme in the vasculature, attenuates NF-kappaB activation. Arterioscler Thromb Vasc Biol (2007) 1.07
A proteasomal stress response: pre-treatment with proteasome inhibitors increases proteasome activity and reduces neuronal vulnerability to oxidative injury. J Neurochem (2004) 1.05
CHIP represses myocardin-induced smooth muscle cell differentiation via ubiquitin-mediated proteasomal degradation. Mol Cell Biol (2009) 1.05
Proteasome inhibition down-regulates endothelial nitric-oxide synthase phosphorylation and function. J Biol Chem (2006) 1.04
Hydrogen peroxide induces nitric oxide and proteosome activity in endothelial cells: a bell-shaped signaling response. Free Radic Biol Med (2007) 1.00
Regulatory T-cell immunity and its relevance to atherosclerosis. J Intern Med (2008) 0.99
Nitric oxide regulates the 26S proteasome in vascular smooth muscle cells. Nitric Oxide (2009) 0.97
Retracted Oxidized LDL modulates apoptosis of regulatory T cells in patients with ESRD. J Am Soc Nephrol (2009) 0.97
Protection of vascular cells from oxidative stress by proteasome inhibition depends on Nrf2. Cardiovasc Res (2009) 0.96
Sustained oxidative stress inhibits NF-kappaB activation partially via inactivating the proteasome. Free Radic Biol Med (2008) 0.96
Cardiovascular inflammation and lesion cell apoptosis: a novel connection via the interferon-inducible immunoproteasome. Arterioscler Thromb Vasc Biol (2009) 0.95
On and off: proteasome and TGF-beta signaling. Exp Cell Res (2003) 0.95
Proteasome inhibitor bortezomib promotes a rupture-prone plaque phenotype in ApoE-deficient mice. Basic Res Cardiol (2009) 0.94
The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients. Clin Exp Rheumatol (2009) 0.94
Multiple Interactions between Peroxisome Proliferators-Activated Receptors and the Ubiquitin-Proteasome System and Implications for Cancer Pathogenesis. PPAR Res (2008) 0.93
Chaperone-dependent E3 ligase CHIP ubiquitinates and mediates proteasomal degradation of soluble guanylyl cyclase. Am J Physiol Heart Circ Physiol (2007) 0.92
Ciglitazone-induced cellular anti-proliferation increases p27kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation. Cell Signal (2004) 0.91
Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells. Leukemia (2007) 0.91
Increased ubiquitin immunoreactivity in unstable atherosclerotic plaques associated with acute coronary syndromes. J Am Coll Cardiol (2002) 0.88
EGF receptor activity modulates apoptosis induced by inhibition of the proteasome of vascular smooth muscle cells. J Am Soc Nephrol (2006) 0.88
Possible dual role of ubiquitin-proteasome system in the atherosclerotic plaque progression. J Am Coll Cardiol (2008) 0.87
Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells. Immunology (2006) 0.87
Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum Immunol (2007) 0.87
Effects of ubiquitin-proteasome system deregulation on the vascular senescence and atherosclerosis process in elderly patients. J Gerontol A Biol Sci Med Sci (2008) 0.86
Induction of ubiquitin-conjugating enzyme by aggregated low density lipoprotein in human macrophages and its implications for atherosclerosis. Arterioscler Thromb Vasc Biol (2000) 0.86
The -8 UTR C/G polymorphism of PSMA6 gene is associated with susceptibility to myocardial infarction in type 2 diabetic patients. Atherosclerosis (2008) 0.85
Potential role of CYLD (Cylindromatosis) as a deubiquitinating enzyme in vascular cells. Am J Pathol (2008) 0.85
Effect of statins on the proteasomal activity in mammalian endothelial and vascular smooth muscle cells. Biochem Pharmacol (2005) 0.85
Protection against amyloid beta cytotoxicity by sulforaphane: role of the proteasome. Arch Pharm Res (2009) 0.85
The functional variant rs1048990 in PSMA6 is associated with susceptibility to myocardial infarction in a Chinese population. Atherosclerosis (2009) 0.84
Control of LMP7 expression in human endothelial cells by cytokines regulating cellular and humoral immunity. Cytokine (2000) 0.83
The expression of vascular dendritic cells in human atherosclerotic carotid plaques. Hum Pathol (2007) 0.83
Validation of the association between the gene encoding proteasome subunit alpha type 6 and myocardial infarction in a Japanese population. Circ J (2007) 0.82
Inhibition of the ubiquitin-proteasome system: a new avenue for atherosclerosis. Clin Chem Lab Med (2006) 0.81
SNPs of PSMA6 gene--investigation of possible association with myocardial infarction and type 2 diabetes mellitus. Genetika (2007) 0.80
The proteasome inhibitor lactacystin attenuates growth and migration of vascular smooth muscle cells and limits the response to arterial injury. Exp Clin Cardiol (2007) 0.79
The ubiquitin-proteasome system--micro target for macro intervention? Int J Cardiovasc Intervent (2005) 0.78
Relationship of the 20S proteasome and the proteasome activator PA28 to atherosclerosis and intimal hyperplasia in the human vascular system. Ann Vasc Surg (2001) 0.77
The proteasome and intracellular redox status: implications for apoptotic regulation in lens epithelial cells. Curr Eye Res (2007) 0.77
Pathophysiological role of proteasome-dependent proteolytic pathway in endothelin-1-related cardiovascular diseases. Curr Vasc Pharmacol (2003) 0.76
Systematic review: transient left ventricular apical ballooning: a syndrome that mimics ST-segment elevation myocardial infarction. Ann Intern Med (2004) 11.40
Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J (2008) 9.50
Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol (2003) 6.04
Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol (2004) 4.62
Clinical features, management, and prognosis of spontaneous coronary artery dissection. Circulation (2012) 4.13
Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol (2010) 3.63
Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol (2006) 3.25
Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J (2010) 3.22
Clinical characteristics and thrombolysis in myocardial infarction frame counts in women with transient left ventricular apical ballooning syndrome. Am J Cardiol (2004) 3.19
Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation (2003) 2.81
The assessment of endothelial function: from research into clinical practice. Circulation (2012) 2.68
High leukocyte count is associated with peripheral vascular dysfunction in individuals with low cardiovascular risk. Circ J (2012) 2.61
Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol (2006) 2.57
The interaction between coronary endothelial dysfunction, local oxidative stress, and endogenous nitric oxide in humans. Hypertension (2008) 2.56
Myocardial bridging. Eur Heart J (2005) 2.56
Chronic proteasome inhibition contributes to coronary atherosclerosis. Circ Res (2007) 2.55
Four-year recurrence rate and prognosis of the apical ballooning syndrome. J Am Coll Cardiol (2007) 2.53
Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol (2003) 2.52
Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation (2007) 2.43
Endothelial progenitor cells restore renal function in chronic experimental renovascular disease. Circulation (2009) 2.24
Intravascular ultrasound-guided treatment for angiographically indeterminate left main coronary artery disease: a long-term follow-up study. J Am Coll Cardiol (2005) 2.21
Comparison of mathematic models for assessment of glomerular filtration rate with electron-beam CT in pigs. Radiology (2007) 2.17
Preserved oxygenation despite reduced blood flow in poststenotic kidneys in human atherosclerotic renal artery stenosis. Hypertension (2010) 2.17
Assessment of renal hemodynamics and function in pigs with 64-section multidetector CT: comparison with electron-beam CT. Radiology (2007) 2.14
The long-term effect of coronary stenting on epicardial and microvascular endothelial function. Circ Cardiovasc Interv (2012) 2.03
Distinct renal injury in early atherosclerosis and renovascular disease. Circulation (2002) 2.01
Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol (2005) 2.00
Mechanisms of renal structural alterations in combined hypercholesterolemia and renal artery stenosis. Arterioscler Thromb Vasc Biol (2003) 1.91
Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol (2006) 1.90
Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation (2007) 1.89
The chemokine monocyte chemoattractant protein-1 contributes to renal dysfunction in swine renovascular hypertension. J Hypertens (2009) 1.88
Cortical microvascular remodeling in the stenotic kidney: role of increased oxidative stress. Arterioscler Thromb Vasc Biol (2004) 1.87
Ubiquitin and ubiquitin-like proteins in protein regulation. Circ Res (2007) 1.87
Effect of long-term hormone replacement therapy on coronary endothelial function in postmenopausal women. Mayo Clin Proc (2004) 1.80
Simvastatin abates development of renal fibrosis in experimental renovascular disease. J Hypertens (2008) 1.78
Mortality differences between men and women after percutaneous coronary interventions. A 25-year, single-center experience. J Am Coll Cardiol (2008) 1.78
Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome. Eur Heart J (2009) 1.77
Long-term outcomes of fractional flow reserve-guided vs. angiography-guided percutaneous coronary intervention in contemporary practice. Eur Heart J (2013) 1.76
Acute heart failure in apical ballooning syndrome (TakoTsubo/stress cardiomyopathy): clinical correlates and Mayo Clinic risk score. J Am Coll Cardiol (2011) 1.74
Potential role of the ubiquitin-proteasome system in atherosclerosis: aspects of a protein quality disease. J Am Coll Cardiol (2008) 1.74
Antioxidant intervention blunts renal injury in experimental renovascular disease. J Am Soc Nephrol (2004) 1.70
Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. FASEB J (2006) 1.69
Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension (2008) 1.67
Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression. J Am Coll Cardiol (2009) 1.67
Human renovascular disease: estimating fractional tissue hypoxia to analyze blood oxygen level-dependent MR. Radiology (2013) 1.65
Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina. Eur Heart J (2006) 1.63
Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect. Atherosclerosis (2011) 1.59
Role of circulating osteogenic progenitor cells in calcific aortic stenosis. J Am Coll Cardiol (2012) 1.59
Coronary endothelial dysfunction in patients with early coronary artery disease is associated with the increase in intravascular lipid core plaque. Eur Heart J (2013) 1.59
Enhanced external counterpulsation for ischemic heart disease: what's behind the curtain? J Am Coll Cardiol (2003) 1.59
Coronary microcirculatory vasodilator function in relation to risk factors among patients without obstructive coronary disease and low to intermediate Framingham score. Eur Heart J (2009) 1.58
Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation (2002) 1.57
Early experimental obesity is associated with coronary endothelial dysfunction and oxidative stress. Am J Physiol Heart Circ Physiol (2006) 1.56
Renal vein cytokine release as an index of renal parenchymal inflammation in chronic experimental renal artery stenosis. Nephrol Dial Transplant (2013) 1.56
Impact of gender and age on in vivo virtual histology-intravascular ultrasound imaging plaque characterization (from the global Virtual Histology Intravascular Ultrasound [VH-IVUS] registry). Am J Cardiol (2009) 1.56
Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol (2008) 1.55
The dynamic vasa vasorum. Cardiovasc Res (2007) 1.53
Tissue characterisation using intravascular radiofrequency data analysis: recommendations for acquisition, analysis, interpretation and reporting. EuroIntervention (2009) 1.53
Sex differences in atheroma burden and endothelial function in patients with early coronary atherosclerosis. Eur Heart J (2008) 1.53
Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke (2008) 1.52
Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol (2008) 1.51
The use of magnetic resonance to evaluate tissue oxygenation in renal artery stenosis. J Am Soc Nephrol (2008) 1.51
Normal vascular function as a prerequisite for the absence of coronary calcification in patients free of cardiovascular disease and diabetes. Circ J (2012) 1.51
Remote ischemic preconditioning immediately before percutaneous coronary intervention does not impact myocardial necrosis, inflammatory response, and circulating endothelial progenitor cell counts: a single center randomized sham controlled trial. Catheter Cardiovasc Interv (2012) 1.51
Transient cardiac apical ballooning syndrome: prevalence and clinical implications of right ventricular involvement. J Am Coll Cardiol (2006) 1.51
Blood oxygen level-dependent measurement of acute intra-renal ischemia. Kidney Int (2004) 1.50